Current medical news and unique business news for anyone who cares about healthcare.
A Medicaid mess in California. A group of pharmacists and medical associations have sued the California Department of Health Care Services and the U.S. Department of Health and Human Services over a 10 percent Medicaid reimbursement rate cut recently approved by the the Centers for Medicare and Medicaid Services, alleging that the cuts did not go through the proper legal process. A related case stemming from several bills passed for reimbursement cuts is being considered by the U.S. Supreme Court. In that case, California providers sued the DHCS seeking preliminary injunctions against the cuts to Medi-Cal.
Trading nicotine for a vaccine. Massachusetts-based Selecta Biosciences is testing a smoking vaccine that would train your body to capture nicotine in the bloodstream, barring them from entering your brain, keeping cigarettes from causing any calming or appetite-reducing effects that many smokers seek. It’s raised nearly $80 million to develop the vaccine using nanoparticles.
The Power of Real World Data to Study Women’s Health at Scale
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Why don’t we have a cure by now? It’s the question that begs to be asked, as billions of dollars are pumped into cancer research each year. Scientist Michael Long wants to remind us that lots of times research fails, but even when it does it still adds something to the big puzzle — even if it’s just what not to do in the future. And, cancer as we’ve come to know it implies a single disease, when in fact it’s a multitude of diseases requiring different approaches. We’ve come a long way, folks.
East Coast/West Coast. Speaking of failure, KPCB partner Dana Mead says that one of Silicon Valley’s most beneficial traits for its entrepreneurial success is its entrepreneurs’ ability to embrace failure. Cambridge, on the other hand, isn’t quite as unconditionally supporting, he claims.
The trouble with university tech transfer. It’s a tricky venture just like any other, but technology transfer depends on these three factors: product-market fit, people and resources.